SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Trump Criticizes ABC, NBC and CNN for Limiting Coverage of Election Speech 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
NTSB Leads Investigation Into Ryanair Boeing 737 Engine Failure Over Greece 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
PayPal Rejects $53 Billion Stripe-Advent Takeover Offer as Too Low: Report 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Sam Altman Admits OpenAI Missteps, Promises Major AI Comeback Focused on User Freedom 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
SK bioscience, a South Korean pharmaceutical firm, announced on Thursday, March 21, that it has exported its influenza vaccine to Thailand. The company developed a cell-cultured influenza vaccine, and after securing the required approvals and permits, it started exporting its Sky Cellflu to the country.
First Batch of Deliveries
According to The Korea Herald, SK Bioscience has already completed the first delivery, which consists of 440,000 doses of the Sky Cellflu vaccine. The products were handed over to its local partner, Biogenetech.
The Korean pharmaceutical company expects to receive more orders and expand its sales once the new influenza vaccine is distributed in Thailand. The deal also marks SK Bioscience's expansion in the Southeast Asian market and entry into the Southern space.
Timely Arrival of the Flu Vaccines
Korea IT Times reported that Thailand has been affected by flu strains, and vaccination is being sought to prevent infections. SK bioscience's Sky Cellflu was also approved by the World Health Organization (WHO) for use in the country.
Moreover, this export is expected to become an excellent example of proper vaccination to combat influenza. Meanwhile, Sky Cellflu already secured proper licenses for distribution in 12 countries, including Malaysia, Thailand, Chile, Singapore, Mongolia, and Pakistan.
World's First Cell Culture-Based Flu Vaccine
SK bioscience's SKYCellflu is said to be the first cell culture-based influenza vaccine in the world. It obtained WHO Pre-qualification (PQ) certification for safe usage and dissemination worldwide.
"The export of SKYCellflu to Thailand serves as a stepping-stone for entering the Southeast Asian and Southern Hemisphere markets and expanding into the global market," SK bioscience's chief executive officer, Ahn Jae Yong, said in a press release. "In addition to diversifying our existing product markets, we are committed to developing vaccines with blockbuster potential, such as our next-generation pneumococcal conjugate vaccine candidate, which is expected to enter phase III clinical trials this year."
Photo by: SK Bioscience Press Release
